![Quiver Logo](/static/img/logo-icon.png)
![ELTX logo](https://quiver-logos.s3.us-east-2.amazonaws.com/eltx.png)
Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ELTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ELTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ELTX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ELTX
Recent picks made for ELTX stock on CNBC
ETFs with the largest estimated holdings in ELTX
Flights by private jets registered to ELTX
![Quiver Logo](/static/img/logo-icon.png)